http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
( Sang Hoon Ahn ),( Won Hyeok Choe ),( Yoon Jun Kim ),( Jeong Heo ),( Dorota Latarska-smuga ),( Jiho Kang ),( Seung Woon Paik ) 대한간학회 2017 춘·추계 학술대회 (KASL) Vol.2017 No.1
Aims: Chronic Hepatitis C Virus (HCV) infection increases the risk for progressive liver disease, hepatocellular carcinoma and negatively impacts the patient’s quality of life. HCV treatment is evolving with direct acting antivirals but IFN based therapy has been the standard of care for many years and remains available in some countries. The MOSAIC study aims to characterize patients with chronic HCV infection and assess the impact of IFN-containing treatment on health-related quality of life, work related productivity and health care utilization. Methods: MOSAIC is an international prospective multicenter observational study that has been conducted in 20 countries. Consecutive patients with chronic HCV infection were enrolled and those who initiated an IFN based regimen were prospectively followed for 48 weeks. We report results from the Korean cohort Results: 100 patients were enrolled: 86 were treatment naïve and 14 were treatment experienced. 33 patients initiated an IFN based regimen: 6 patients started IFN + RBV, 26 patients started Peg-IFN + RBV, none started Peg-IFN + RBV + DAA and 1 patient received other treatment. Among the treated cohort, demographic and disease characteristics were the following: the mean age was 54.5 years; 14 patients were male. 14 had minimal or no fibrosis, 2 portal fibrosis, 3 bridging fibrosis and 6 patients suffered from cirrhosis. HCV Genotype distribution was as follows: genotype 1: 11; genotype 2: 19 and genotype 3: 3. Table 1 describes the results at baseline and changes over 4, 12 and 48 weeks and end-of-treatment (EOT) for the quality of life and work productivity outcome measures (EQ-5D-5L, HCV-PRO and WPAI). Conclusions: Results from the Korean cohort of the MOSAIC study show a moderate trend for deterioration of health-related quality of life and work productivity associated with IFN based treatment for patients with chronic HCV infection during treatment period. Acknowledgements: The design, study conduct, analysis, and financial support of MOSAIC study were provided by AbbVie. AbbVie participated in the interpretation of data, review, and approval of the content of the abstract. All authors had access to all relevant data and participated in writing, review, and approval of this abstract. Medical writing support was provided by Olivier Van de Steen of Medeor-consulting, funded by AbbVie. Disclosures: Sang Hoon Ahn: served as an advisor and lecturer for Bristol-Myers Squibb, Gilead Sciences, F.Hoffmann-La Roche, Merck, AbbVie, and has received unrestricted grants from Bristol-Myers Squibb, Gilead Sciences, and F. Hoffmann-La Roche for investigator- initiated trials Won Hyeok Choe: Nothing to disclosure Yoon Jun Kim: Nothing to disclosure Jeong Heo: received a grant from GSK; Research support from BMS, and Roche; Advisor for Abbvie, BMS, Gilead Sciences, Pharma Essentia, SillaJen, and Johnson & Johnson. Dorota Latarska-Smuga, Jiho Kang: are employees of AbbVie, Inc. and may hold stock or stock options. Seung Woon Paik: received grant and research support from AbbVie, BMS, Gilead, GSK, Merck, Novartis, and Roche
단상 멀티레벨 능동전력필터를 위한 고조파 검지 기법 비교
김윤호(Yoon-Ho Kim),김수홍(Soo-Hong Kim),김성민(Sung-Min Kim),서강문(Kang-Moon Seo) 전력전자학회 2005 전력전자학술대회 논문집 Vol.- No.-
In this paper, harmonic detecting methods for the active power application are investigated. They are RDFT, Kalman Filter, Adaptive predictive filter, Instantaneous reactive power detecting method, Improved adaptive filter detecting method. The 5 harmonic detecting methods are simulated and their characteristics for the active filter application are compared using simulation results.
Chung, Sung Yun,Kim, Sunyoung,Lee, Ju‐,Hyuck,Kim, Kyongjun,Kim, Sang‐,Woo,Kang, Chong‐,Yun,Yoon, Seok‐,Jin,Kim, Youn Sang WILEY‐VCH Verlag 2012 ADVANCED MATERIALS Vol.24 No.45
<P>An all‐solution‐processed flexible piezoelectric nanogenerator, composed of polycrystalline ZnO thin film and functional polymer layers such as P3HT/PCBM and PEDOT:PSS, generates energy through a mechanical rolling and muscle stretching system. On page 6022, Youn Sang Kim, Sang‐Woo Kim, and co‐workers show that this all‐solution‐processed nanogenerator is feasible as a piezoelectric patchable device and is promising for use in future energy harvesters such as wearable human patches and mobile electronics. </P>
The Results of Curative Radiotherapy for Carcinoma of Uterine Cervix
Ryu, Ryeong,Chang, Gee Young,Namkong, Sung Eun,Bahk, Yong Whee,Shinn, Kyung Sub,Kim, Seung Jo,Suh, Tae Suk,Yoon, Sei Chul,Kang, Ki Mun CATHOLIC MEDICAL CENTER 1994 Bulletin of the Clinical Research Institute Vol.22 No.2
One-hundred five patients with invasive carcinoma of the uterine cervix treated with curative radiotherapy from March 1983 through October 1989 at the Department of Therapeutic Radiology, Kang-Nam St. Mary's Hospital. Among them, 78 patients received radiotherapy alone and 42 patients treated with neoadjuvant chemotherapy followed by radiotherapy and 15 patients were lost to follow up. All patients had follow up from 2 to 106 months (median; 62 months). Age of the patients ranged from 32 to 79 years at presentation (median; 59 years). The overall 5-year survival rates was 50.8%, and the 5-year survival rates by stage ⅠB, ⅡA, ⅡB, ⅢA, ⅢB, ⅣA was 47.7%, 70.2%, 64.1%, 40.0%, 23.1%, 14.3%, respectively. The 5-year survival rates was noted 51.2% of radiotherapy alone and 50.4% of neoadjuvant chemotherapy followed by radiotherapy. The overall failure rate was 18.3% (22/120) including 11.7% (14/120) locoregional failure, 5.8% (7/120) distant metastasis and 0.8% (1/120) locoregional failure with distant metastasis. Treatment failure rates by the stages were 15% (3/20) in stage ⅠB, 10.5% (2/19) in stage ⅡA, 10.2% (5/49) in stage ⅡB, 20% (1/5) for stage ⅢA, 61.5% (8/13) in stage ⅢB, and 28.6% (4/14) in stage ⅣA. The overall complication rate was 34.2% (41/120), including wet desquamation 7.5% (9/120), diarrhea 6.7% (8/120), radiation proctitis 5.8% (7/120) in decreasing order. A multivariate analysis of factors influencing the survival showed patient age (P=0.0291), FIGO stage (P=0.0001), Karnofsky performance status (P=0.0043), initial hemoglobin level (P=0.0001), and intracavitary radiation (P=0.0004), but, no significancy in histology (P=0.29) and teatment method (P=0.87).
The Results of Curative Radiotherapy for Carcinoma of Uterine cervix
강기문,유미령,장지영,서태석,윤세철,박용휘,신경섭,남궁성은,김승조,Kang Ki Mun,Ryu Mi Ryeong,Chang Gee Young,Suh Tae Suk,Yoon Sei Chul,Bahk Yong Whee,Shinn Kyung Sub,Namkoong Sung Eun,Kim Seung Jo The Korean Society for Radiation Oncology 1993 Radiation Oncology Journal Vol.11 No.1
가톨릭의과대학 강남성모병원 치료방사선과에서 1983년 3월부터 1989년 10월까지 79개월 동안에 자궁경부암으로 근치적 방사선치료를 받았던 135명의 환자들 중에서 추적이 가능하였던 120명의 환자들을 대상으로 치료결과및 예후에 영향을 미치는 인자에 대하여 후향적 분석을 하였다. 방사선 단독으로 치료한 환자는 78명이었고 유도 화학요법을 방사선 치료전에 시행한 환자는 42명이었다. 대상 환자들의 추적 조사기간은,2개월에서 106개월이었고 중간 추적조사 기간은 62개월이었다. 환자들의 나이는 32세부터 79세까지의 분포를 보였다(중앙값, 59세). FIGO 병기별 분류에 의하면, IB 기가 20명 ($16.7{\%}$), IIA 기가 19명 ($15.8{\%}$), IIB기가 49명 ($40.8{\%}$), IIIA 기가 5명 ($4.2{\%}$), IIIB기가 13명 ($10.8{\%}$), IVA 기가 14명 ($11.7{\%}$)이었다. 전체환자의 5년 생존율은 $50.8{\%}$였다. 병기별 5년 생존율은 IB 기가 $47.7{\%}$ IIA 기가 $70.2{\%}$, IIB 기가 $64.1{\%}$, IIIA 기가 $40.0{\%}$, IIIB 기가 $23.1{\%}$, IVA 기가 $14.3{\%}$였다. 치료방법에 따른 5년 생존율은 방사선 단독으로 치료한 환자가 $51.2{\%}$였고, 유도화학요법을 방사선 치료전에 시행한 환자는 $54.0{\%}$였다. 치료후 재발은 22명 ($18.3{\%}$,)에서 관찰되었고, 이중 14명 ($11.7{\%}$)에서 국소재발이, 7명 ($5.8{\%}$)에서 원격전이가, 1명 ($0.8{\%}$)에서 국소재발과 원격전이가 함께 발생하였다. 그리고, 치료에 의한 합병증은 41명 ($34.2{\%}$)에서 관찰되었으며 9명 ($7.5{\%}$)에서 습낙설, 8명 ($7.5{\%}$)에서 설사, 7명 ($5.8{\%}$)에서 방사선 직장염의 순으로 발생하였다. 예후와 관련된 생존율에 영향을 주었던 인자로는 나이 (p<0.0291), 병기(p<0.0001), 전신상태(p<0.0041), 초기 혈색소 수치 (p<0.0001), 강내 조사(p<0.0004)였고, 조직학적 소견(p<0.29), 유도 화학요법과의 병행치료(p<0.87)는 통계학적으로 유의하지 않았다. This is a retrospective analysis of 135 patients with invasive carcinoma of the uterine cervix treated with curative radiotherapy from March 1983 through October 1989 at the Department of Therapeutic Radiology, Kang-Nam 51. Mary's Hospital. Among them, 78 patients received radiotherapy alone and 42 patients treated with neoadjuvant chemotherapy followed by radiotherapy and 15 patients were lost to follow up. All patients had follow up from 2 to 106 months (median; 62 months). Age of the patients ranged from 32 to 79 years at presentation (median; 59 years). According to FIGO classification, there were 20 ($16.7{\%}$) in stage IB, 19 ($15.8{\%}$) in stage IIA,49 ($40.8{\%}$) in stage IIB, 5 ($4.2{\%}$) in stage IIIA, 13 ($10.8{\%}$,) in stage IIIB,14 ($11.7{\%}$) in stage IVA. The pathological classification showed 96 ($80.0{\%}$) squamous cell carcinomas, 5 ($4.2{\%}$) adenocarcinomas and 19 ($15.8{\%}$) proven by cytology. The overall 5-year survival rates was $50.8{\%}$, and the 5-year survival rates by stage IB, IIA, IIB, IIIA, IIIB, IVA was $47.7{\%},\;70.2{\%},\;64.1{\%},\;40.0{\%},\;23.1{\%},\;14.3{\%}$, respectively. The 5-year survival rates was noted $51.2{\%}$ of radiotherapy alone and $50.4{\%}$of neoadjuvant chemotherapy followed by radiotherapy. The overall failure rate was $18.3{\%}$(22/120) including $11.7{\%}$ (14/120) locoregional failure, $5.8{\%}$ (7/120) distant metastasis and $0.8{\%}$(1/120) locoregional failure with distant metastasis. Treatment failure rates by the stages were $15{\%}$ (3/20) in stage IB. $10.5{\%}$ (2/19) in stage IIA, $10.2{\%}$, (5/49) in stage IIB, $20{\%}$ (1/5) in stage IIIA, $61.5{\%}$(8/13) in stage IIB, and $28.6{\%}$ (4/14) in stage IVA. The overall complication rate was $34.2{\%}$(41/120) including wet desquamation $7.5{\%}$, (9/120), diarrhea $6.7{\%}(8/120), radiation proctitis $5.8{\%}$(7/120) in decreasing order. A multivariate analysis of factors influencing the survival showed patient age (p < 0.0291), FIGO stage (p<0.0001), Karnofsky performance status (p<0.0043), initial hemoglobin level (p<0.0001), and intracavitary radiation (p<0.0004), but, no significancy in histology (p<0.29) and treatment method (p < 0.87).
( Yoon Yung Chung ),( Kang Moon Lee ),( Ji Min Lee ),( Dae Bum Kim ),( Hea Jung Sung ),( Woo Chul Chung ),( Chang Nyol Paik ),( Yeon Ji Kim ),( Hyewon Lee ),( Yeon Oh Jeong ) 대한내과학회 2014 대한내과학회 추계학술대회 Vol.2014 No.1
Background: Recent studies suggest that the diverticular disease (DD) could be considered as a chronic inflammatory bowel disease. It was never investigated about the presence of inflammatory infiltrate in right colonic diverticular disease, and the grading of inflammatory infiltrate according to disease severity. The aim of this study was to assess and grade the mucosal inflammatory infiltrate in different degrees of DD and to compare them with healthy controls. Methods: Thirty consecutive patients with endoscopic diagnosis of DD (10 with asymptomatic diverticulosis, 10 with symptomatic uncomplicated DD, and 10 with acute uncomplicated diverticulitis) and 10 healthy controls were enrolled. They underwent colonoscopy, and 2~4 biopsy samples of colonic mucosa were collected in the right colon. In DD, biopsies were taken in the peridiverticular area. The presence of inflammatory infiltrate was assessed by a semi-quantitative lymphocytes and neutrophils count. Immunohistochemical staining was performed using anti-CD3 monoclonal antibodies for lymphocytes, and anti-CD15 monoclonal antibodies for neutrophils. Results: The mean lymphocytic cell density was significantly increased according to the degree of DD (P=0.000) (Table 1). There was higher lymphocytic cell density even in asymptomatic diverticulosis than healthy controls. A neutrophilic inflammatory in- filtrate was found only in acute uncomplicated diverticulitis. Conclusions: Microscopic inflammatory infiltration was increased according to the degree of right-sided DD. There was higher inflammatory cell density even in asymptomatic diverticulosis than healthy controls, which implies that right-sided diverticulosis may be considered as chronic inflammatory disease.